Skip to Main Content

Paper Details

Use of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagonlike Peptide-1 Receptor Agonists in Patients With Diabetes and Cardiovascular Disease in Community Practice.
JAMA Cardiol
10
2023
ASCVD, Cardiovascular Disease, Diabetes, GLP-1, GLP-1 RA, Glucagonlike Peptide-1 Receptor, Glucose, Patients, SGLT2i, Sodium-, Sodium-Glucose Cotransporter 2, Sulfonylureas, T2D, atherosclerotic cardiovascular disease, chronic kidney disease, dipeptidyl peptidase 4, end-stage kidney disease, glucagonlike peptide-1 receptor, glucose, patients, persons, sodium, sodium-glucose cotransporter 2, type 2 diabetes
Author NameAffiliation
Eric D PetersonUT Southwestern Medical Center
Eric D PetersonUT Southwestern Medical Center
Ann Marie NavarUT Southwestern Medical Center
Ann Marie Navar
  • 1 - 4

Datasets

Release 1.2